EN DE
Watch AP Biosciences Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AP Biosciences Inc (6945) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of AP Biosciences Inc stock TWD 79.71, price TWD 115, that is 30.7% below the price, quality 36 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006945009

AB AP Biosciences Inc logo Thin data Nov 10, 2026

AP Biosciences Inc

6945 · TWO
Weak valuation

Our calculation puts a fair price 31% below what the stock costs today.

Mixed vs. peers (4/7)
Fair value 79.71 TWD · Overvalued
Quality 36/100
Weak Growth (revenue 3y −38.3 %/yr in TWD)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch AP Biosciences Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

231.50 TWD 87.00 TWD Fair Value 79.71 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

11‑month range 87.00 TWD – 231.50 TWD · fair‑value band 59.78 TWD – 99.64 TWD · the 115.00 TWD price screens above the 79.71 TWD fair value. As of Nov 10, 2026.

Follow AP Biosciences in your weekly email

Every Wednesday you see whether AP Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs.

Show moreShow less

It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors.

It caters to healthcare and biotechnology industries. AP Biosciences, Inc. has strategic collaboration with Delos Capital to discover and develop novel immune-related drug candidates through early clinical proof of concept. The company was founded in 2013 and is based in Taipei, Taiwan.

Stock analysis

AP Biosciences Inc (6945) currently trades at 115.00 TWD, while our estimate is 79.71 TWD, 31% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 59.78 TWD (bear) to 99.64 TWD (bull), the price of 115.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

AP Biosciences Inc reported revenue of 0 TWD in FY2025 versus 7.0M TWD in FY2021. Reported net income was −445M TWD in FY2025.

Key figures

Market cap 12.8B TWD (≈ $389M) Small · EPS (TTM) −5.40 TWD · Return on equity −24.5% · Return on assets (EBIT) −31.2% (5-year average) · Free cash flow −377M TWD · Net cash 1.4B TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −31%, 6945 screens richer than that median.

Fair Value

Bear 59.78 TWD Fair Value 79.71 TWD Bull 99.64 TWD
Price 115.00 TWD · Downside -30.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6945 screens overvalued: fair value 31% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare AP Biosciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −30.7% · Below median
Profitability
Return on assets −32.6% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.31× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 6945
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 6945
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 6945
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 6945
argenx SE ARGX $971.55 $908.40 −7% vs 6945
CSL Limited CSL A$201.68 A$181.40 −10% vs 6945
Moderna, Inc MRNA $250.83 $158.70 −37% vs 6945
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 6945
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 6945
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 6945

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AP Biosciences Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AP Biosciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/6945

Frequently asked questions

Is AP Biosciences Inc (6945) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 79.71 TWD versus a price of 115.00 TWD, about 31% lower (overvalued).
What is the fair value of 6945?
Our estimate for AP Biosciences Inc is 79.71 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 115.00 TWD.
What is the quality score of 6945?
AP Biosciences Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AP Biosciences Inc (6945)?
Our calculated price target is the estimate of 79.71 TWD (as of Nov 10, 2026). Cautious scenario 59.78 TWD, optimistic scenario 99.64 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the AP Biosciences Inc stock forecast for 2026?
Our estimate puts fair value at 79.71 TWD, about 31% lower versus a price of 115.00 TWD (overvalued). Cautious scenario 59.78 TWD, optimistic scenario 99.64 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of AP Biosciences Inc (6945)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AP Biosciences Inc it is 79.71 TWD per share (as of Nov 10, 2026), against a price of 115.00 TWD.
Is AP Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6945 trades above its calculated fair value: price 115.00 TWD, fair value 79.71 TWD, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6945?
No. The price is what the market pays today (115.00 TWD); the fair value is what the company's own numbers justify (79.71 TWD). For AP Biosciences Inc the two are 35.29 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is AP Biosciences Inc worth?
The market values AP Biosciences Inc at about 12.8B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 115.00 TWD; our models calculate a fair value of 79.71 TWD per share.
What do the bullish and bearish scenarios say about 6945?
Our models span a range for AP Biosciences Inc: cautious scenario 59.78 TWD, base 79.71 TWD, optimistic 99.64 TWD per share (as of Nov 10, 2026, price 115.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AP Biosciences Inc (6945)?
Balance-sheet figures for AP Biosciences Inc (as of Nov 10, 2026): return on equity −24.5%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 6945 from its 52-week high?
AP Biosciences Inc trades at 115.00 TWD, about 50% below its 52-week high of 231.50 TWD and 32% above the low of 87.00 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 79.71 TWD is for.
Which stocks are comparable to AP Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AP Biosciences Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 115.00 TWD, calculated fair value 79.71 TWD (−31%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. AP Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AP Biosciences Inc (6945)?
The closing price on Nov 10, 2026 was 115.00 TWD. Our estimate is 79.71 TWD, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AP Biosciences Inc right now?
The price sits above even our optimistic bull case (99.64 TWD). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of AP Biosciences Inc

How large is the market capitalisation of AP Biosciences Inc (6945)?
The market capitalisation of AP Biosciences Inc is 12.8B TWD (≈ $389M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of AP Biosciences Inc (6945)?
Earnings per share at AP Biosciences Inc are −5.40 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of AP Biosciences Inc (6945)?
The return on equity (ROE) of AP Biosciences Inc is −24.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AP Biosciences Inc (6945)?
On an EBIT basis the return on assets of AP Biosciences Inc is −31.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does AP Biosciences Inc (6945) generate?
The free cash flow of AP Biosciences Inc is −377M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does AP Biosciences Inc (6945) hold?
AP Biosciences Inc holds more cash than debt, 1.4B TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AP Biosciences Inc in the live analysis

One click puts AP Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.